You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test is now approved as a CDx for advanced ovarian cancer patients considering Lynparza as a first-line maintenance treatment.
The group recommends Myriad Genetics' EndoPredict, NanoString's Prosigna, and Genomic Health's Oncotype DX tests for guiding chemotherapy decisions if certain conditions are met.
There were more mergers and acquisitions in the omics space in 2018, reversing the decline experienced in 2017.
At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes.
The studies involved data from 14,000 Hispanic women and showed the 87-SNP risk score outperformed its 86-SNP score for European women.
PacBio's shares skyrocketed 76 percent in November on the news that Illumina plans to acquire the firm for $1.2 billion in cash.
The company has entered into an accelerated share repurchase program with the bank to buy back a portion of its common stock.
Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
The test is approved to gauge germline BRCA mutations in advanced breast cancer patients who may benefit from treatment with Pfizer's PARP inhibitor Talzenna.
A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.
A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.
The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.
In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.